Free Trial

Ontrak (OTRK) Competitors

$0.26
-0.02 (-7.27%)
(As of 05/28/2024 ET)

OTRK vs. MGRX, BRTX, GBNHF, AKTX, CHEK, ELAB, DOMH, COEP, DMTK, and IKT

Should you be buying Ontrak stock or one of its competitors? The main competitors of Ontrak include Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), Greenbrook TMS (GBNHF), Akari Therapeutics (AKTX), Check-Cap (CHEK), Elevai Labs (ELAB), Dominari (DOMH), Coeptis Therapeutics (COEP), DermTech (DMTK), and Inhibikase Therapeutics (IKT). These companies are all part of the "medical" sector.

Ontrak vs.

Ontrak (NASDAQ:OTRK) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.

In the previous week, Mangoceuticals had 2 more articles in the media than Ontrak. MarketBeat recorded 6 mentions for Mangoceuticals and 4 mentions for Ontrak. Ontrak's average media sentiment score of 0.69 beat Mangoceuticals' score of 0.56 indicating that Ontrak is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ontrak
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mangoceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ontrak has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Ontrak currently has a consensus price target of $4.00, indicating a potential upside of 1,468.63%. Given Ontrak's higher probable upside, equities research analysts clearly believe Ontrak is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ontrak
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Mangoceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Mangoceuticals has lower revenue, but higher earnings than Ontrak.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ontrak$12.74M0.96-$27.92M-$4.00-0.06
Mangoceuticals$730K14.96-$9.21MN/AN/A

Ontrak received 37 more outperform votes than Mangoceuticals when rated by MarketBeat users.

CompanyUnderperformOutperform
OntrakOutperform Votes
37
58.73%
Underperform Votes
26
41.27%
MangoceuticalsN/AN/A

Ontrak has a net margin of -186.35% compared to Mangoceuticals' net margin of -1,068.72%. Ontrak's return on equity of -304.29% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ontrak-186.35% -304.29% -107.05%
Mangoceuticals -1,068.72%-864.10%-577.68%

13.0% of Ontrak shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 1.6% of Ontrak shares are held by insiders. Comparatively, 39.3% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ontrak beats Mangoceuticals on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTRK vs. The Competition

MetricOntrakhealth & allied services, not elsewhere classified IndustryMedical SectorNASDAQ Exchange
Market Cap$12.23M$2.12B$5.00B$8.09B
Dividend YieldN/A2.09%2.74%3.96%
P/E Ratio-0.0616.74176.4818.43
Price / Sales0.965.902,386.6172.31
Price / CashN/A12.4533.0728.77
Price / Book0.693.864.944.39
Net Income-$27.92M$74.19M$104.35M$213.55M
7 Day Performance-4.85%-5.09%-0.63%-0.80%
1 Month Performance-12.97%-0.55%3.85%3.42%
1 Year Performance-91.01%-23.66%5.47%7.53%

Ontrak Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGRX
Mangoceuticals
0 of 5 stars
$0.52
+101.8%
N/A-60.5%$12.79M$844,866.000.003Short Interest ↓
High Trading Volume
BRTX
BioRestorative Therapies
2.9198 of 5 stars
$1.26
-2.3%
N/AN/A$8.53M$150,000.00-0.3611Short Interest ↓
GBNHF
Greenbrook TMS
0 of 5 stars
$0.09
flat
N/AN/A$3.72M$73.79M0.00492
AKTX
Akari Therapeutics
0 of 5 stars
$1.64
+7.9%
N/A-47.3%$12.95MN/A0.009Analyst Forecast
Short Interest ↑
Positive News
CHEK
Check-Cap
0 of 5 stars
$2.22
+1.4%
N/A+55.5%$12.96MN/A-0.7385Upcoming Earnings
Analyst Forecast
News Coverage
Positive News
ELAB
Elevai Labs
0 of 5 stars
$0.68
flat
N/AN/A$12.75M$1.71M-1.8218Short Interest ↑
Positive News
Gap Up
DOMH
Dominari
0.8936 of 5 stars
$2.14
+0.5%
N/A-14.2%$12.69M$2.04M-0.4626Short Interest ↑
Gap Down
COEP
Coeptis Therapeutics
2.3854 of 5 stars
$0.34
flat
$3.00
+790.2%
-85.4%$12.51M$80,000.00-0.645Short Interest ↓
Gap Up
DMTK
DermTech
1.7374 of 5 stars
$0.36
-2.7%
$2.38
+569.5%
-84.2%$12.41M$15.30M-0.13206Short Interest ↓
News Coverage
Positive News
Gap Down
IKT
Inhibikase Therapeutics
1.5418 of 5 stars
$1.89
+1.6%
$23.00
+1,116.9%
-51.0%$12.25M$260,000.00-0.578Gap Up

Related Companies and Tools

This page (NASDAQ:OTRK) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners